Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single and Multiple Ascending Dose Study of LY3002813 in Alzheimer's Disease
jRCT2080222069Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1 trial of donanemab in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Safety and tolerability of LY3002813 and Pharmacokinetics of LY3002813. Started May 2013; status: completed.
02
Drugs
donanemab
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on jRCT2080222069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222069.